A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies
Phase of Trial: Phase II
Latest Information Update: 15 May 2019
Price : $35 *
At a glance
- Drugs Testosterone cipionate (Primary) ; Testosterone enanthate (Primary) ; Abiraterone acetate; Enzalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms RESTORE
- 10 May 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2021.
- 10 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2021.
- 31 Aug 2018 Biomarkers information updated